Nippon Life Global Investors Americas Inc. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nippon Life Global Investors Americas Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 840 shares of the biopharmaceutical company’s stock after selling 230 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in Regeneron Pharmaceuticals were worth $883,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. West Paces Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares in the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $28,000. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold a total of 9,270 shares of company stock valued at $10,695,833 in the last quarter. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $1,145.03 on Monday. The firm’s 50-day moving average is $1,131.75 and its two-hundred day moving average is $1,032.63. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The company has a market capitalization of $126.17 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the firm posted $8.79 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and set a $1,282.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 17th. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Piper Sandler boosted their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Canaccord Genuity Group reissued a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,111.30.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.